Extended Data Fig. 5: Pan-cancer and cancer-type-specific priority scores.

a, Criteria for the target prioritization scoring system. b, ANOVA results from differential dependency biomarker analyses with all 1,001 significant associations classified as pan-cancer or cancer-type-specific associations (inner circle), loss- or gain-of-fitness marker (middle circle) and whether the marker is a mutation, copy number gain or loss (outer circle). c, Distributions of pan-cancer (left) and cancer-type-specific (right) non-null target priority scores based on the therapeutic indication of approved or preclinical compounds. The significance threshold was based on the distribution of scores for targets with approved anticancer compounds (specific anticancer compounds for the cancer-type-specific priority score) versus scores for targets with no available anticancer compounds. d, Overlap between cancer-type-specific priority targets (for at least one cancer type) and pan-cancer priority targets. e, Example priority targets identified only in the pan-cancer context. Each symbol is an individual cell line coloured by cancer type and symbol shapes indicate a significant dependency (n = 324 cell lines).